- Home
- SUUN vs GANX Comparison
SUUN vs GANX Comparison
Compare SUUN & GANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SUUN
- GANX
- Stock Information
- Founded
- SUUN 2013
- GANX 2017
- Country
- SUUN Canada
- GANX United States
- Employees
- SUUN N/A
- GANX N/A
- Industry
- SUUN
- GANX Biotechnology: Pharmaceutical Preparations
- Sector
- SUUN
- GANX Health Care
- Exchange
- SUUN Nasdaq
- GANX Nasdaq
- Market Cap
- SUUN 75.1M
- GANX 69.0M
- IPO Year
- SUUN N/A
- GANX 2021
- Fundamental
- Price
- SUUN $1.92
- GANX $1.75
- Analyst Decision
- SUUN Strong Buy
- GANX Strong Buy
- Analyst Count
- SUUN 2
- GANX 5
- Target Price
- SUUN $5.00
- GANX $8.20
- AVG Volume (30 Days)
- SUUN 595.4K
- GANX 555.0K
- Earning Date
- SUUN 09-30-2025
- GANX 08-12-2025
- Dividend Yield
- SUUN N/A
- GANX N/A
- EPS Growth
- SUUN N/A
- GANX N/A
- EPS
- SUUN N/A
- GANX N/A
- Revenue
- SUUN $25,798,969.00
- GANX N/A
- Revenue This Year
- SUUN N/A
- GANX N/A
- Revenue Next Year
- SUUN $46.21
- GANX N/A
- P/E Ratio
- SUUN N/A
- GANX N/A
- Revenue Growth
- SUUN N/A
- GANX N/A
- 52 Week Low
- SUUN $1.23
- GANX $1.00
- 52 Week High
- SUUN $6.43
- GANX $3.19
- Technical
- Relative Strength Index (RSI)
- SUUN 51.64
- GANX 49.48
- Support Level
- SUUN $1.68
- GANX $1.55
- Resistance Level
- SUUN $2.15
- GANX $2.05
- Average True Range (ATR)
- SUUN 0.23
- GANX 0.16
- MACD
- SUUN -0.04
- GANX -0.01
- Stochastic Oscillator
- SUUN 27.59
- GANX 38.46
About SUUN SolarBank Corporation Common Stock
SolarBank Corp is an independent renewable and clean energy project developer and asset operator based in Canada and the United States. It is engaged in the development and operation of solar photovoltaic power generation projects in the province of Ontario and the state of New York. The company operates in two principal geographical areas - Canada and United States with a substantial portion of its overall revenue being generated from United States.
About GANX Gain Therapeutics Inc.
Gain Therapeutics Inc is a biotechnology company developing novel small molecule therapeutics to treat diseases across several therapeutic areas, including, lysosomal storage disorders, central nervous system disorders, metabolic disorders, and oncology. The company's clinical-stage product candidate, GT-02287, is being developed for the treatment of GBA1 Parkinson's disease. The company uses its computational target and drug discovery platform, Magellan, to discover novel allosteric binding sites on proteins implicated in disease and to identify proprietary small molecules that bind these sites to modulate protein function and treat the underlying cause of the disease. Geographically, the company operates in Switzerland, Spain, the United States, and Australia.